UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening

Journal of clinical sleep medicine, 2020-05, Vol.16 (5), p.765-773

2020

Volltextzugriff (PDF)

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

Clinical therapeutics, 2010-07, Vol.32 (7), p.1234-1251

2010

Volltextzugriff (PDF)

Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study

Movement disorders, 2012-09, Vol.27 (10), p.1230-1238

2012

Volltextzugriff (PDF)

The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts

Journal of neurology, neurosurgery and psychiatry, 2010-12, Vol.81 (12), p.1363-1368

2010

Volltextzugriff (PDF)

Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study

Journal of clinical sleep medicine, 2017-11, Vol.13 (11), p.1289-1299

2017

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults

Clinical pharmacology in drug development, 2021-02, Vol.10 (2), p.153-165

2021

Volltextzugriff (PDF)

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents

Psychological medicine, 2022-10, Vol.52 (13), p.2822-2834

2022

Volltextzugriff (PDF)

Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration

Journal of clinical pharmacology, 2014-03, Vol.54 (3), p.282-290

2014

Volltextzugriff (PDF)

Sleep, Sleep Disorders, and Mild Traumatic Brain Injury. What We Know and What We Need to Know: Findings from a National Working Group

Neurotherapeutics, 2016-04, Vol.13 (2), p.403-417

2016

Volltextzugriff (PDF)

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

Sleep (New York, N.Y.), 2019-04, Vol.42 (4), p.1

2019

Volltextzugriff (PDF)

Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial

Clinical and translational science, 2023-04, Vol.16 (4), p.581-592

2023

Volltextzugriff (PDF)

The Association between Insomnia and Insomnia Treatment Side Effects on Health Status, Work Productivity, and Healthcare Resource Use

PloS one, 2015-10, Vol.10 (10), p.e0137117

2015

Volltextzugriff (PDF)

Evidence‐based insomnia treatment strategy using novel orexin antagonists: A review

Neuropsychopharmacology reports, 2021-12, Vol.41 (4), p.450-458

2021

Volltextzugriff (PDF)

Comparison of Pharmacokinetic Profiles of Zolpidem Buffered Sublingual Tablet and Zolpidem Oral Immediate-Release Tablet: Results from a Single-Center, Single-Dose, Randomized, Open-Label Crossover Study in Healthy Adults

Clinical therapeutics, 2013-05, Vol.35 (5), p.604-611

2013

Volltextzugriff (PDF)

Concentration–Response Modeling of ECG Data From Early‐Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk — Experience From the Development Program of Lemborexant

Journal of clinical pharmacology, 2017-01, Vol.57 (1), p.96-104

2017

Volltextzugriff (PDF)

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL

Lancet neurology, 2008-04, Vol.7 (4), p.310-318

2008

Volltextzugriff (PDF)

Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder

Neurology and therapy, 2024-08, Vol.13 (4), p.1081-1098

2024

Volltextzugriff (PDF)

Transitioning insomnia patients from zolpidem to lemborexant: A multicenter, open-label study evaluating a next-dose transition approach to insomnia pharmacotherapy

Sleep medicine. X, 2024-12, Vol.7, p.100098-100098, Article 100098

2024

Volltextzugriff (PDF)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

BMC neurology, 2011-05, Vol.11 (1), p.57-57, Article 57

2011

Volltextzugriff (PDF)

Sleep in women across the life cycle from adulthood through menopause

Sleep Medicine Reviews, 2003-04, Vol.7 (2), p.155-177

2003

Volltextzugriff (PDF)

Re-examining the factor structure of the Insomnia Severity Index (ISI) and defining the meaningful within-individual change (MWIC) for subjects with insomnia disorder in two phase III clinical trials of the efficacy of lemborexant

Journal of patient-reported outcomes, 2024-06, Vol.8 (1), p.65-12, Article 65

2024

Volltextzugriff (PDF)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant

Pharmacology research & perspectives, 2021-04, Vol.9 (2), p.e00758-n/a

2021

Volltextzugriff (PDF)

Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant

Pharmacology research & perspectives, 2020-12, Vol.8 (6), p.e00678-n/a

2020

Volltextzugriff (PDF)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant

Pharmacology research & perspectives, 2021-04, Vol.9 (2), p.e00734-n/a

2021

Volltextzugriff (PDF)

Commentary on Yue et al. Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis

Sleep medicine reviews, 2023-10, Vol.71, p.101816-101816, Article 101816

2023

Volltextzugriff (PDF)

1 – 25 von 193

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(148)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study

The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts

Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study

Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents

Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration

Sleep, Sleep Disorders, and Mild Traumatic Brain Injury. What We Know and What We Need to Know: Findings from a National Working Group

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial

The Association between Insomnia and Insomnia Treatment Side Effects on Health Status, Work Productivity, and Healthcare Resource Use

Evidence‐based insomnia treatment strategy using novel orexin antagonists: A review

Comparison of Pharmacokinetic Profiles of Zolpidem Buffered Sublingual Tablet and Zolpidem Oral Immediate-Release Tablet: Results from a Single-Center, Single-Dose, Randomized, Open-Label Crossover Study in Healthy Adults

Concentration–Response Modeling of ECG Data From Early‐Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk — Experience From the Development Program of Lemborexant

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL

Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder

Transitioning insomnia patients from zolpidem to lemborexant: A multicenter, open-label study evaluating a next-dose transition approach to insomnia pharmacotherapy

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

Sleep in women across the life cycle from adulthood through menopause

Re-examining the factor structure of the Insomnia Severity Index (ISI) and defining the meaningful within-individual change (MWIC) for subjects with insomnia disorder in two phase III clinical trials of the efficacy of lemborexant

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant

Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant

Commentary on Yue et al. Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis

Suchergebnisse filtern